Company background
Pfizer (NYSE: PFE) was founded in 1849 in Brooklyn, New York by German immigrants Charles Pfizer and Charles Erhart. The company built early commercial success on citric acid production, expanded into broader pharmaceutical manufacturing through the 19th and 20th centuries, and pioneered mass penicillin production during World War II — a foundational moment that established Pfizer as a global pharmaceutical leader.
Albert Bourla became CEO of Pfizer in January 2019 succeeding Ian Read. Bourla had been with Pfizer since 1993 and led the company through the COVID-19 vaccine development, the largest pharmaceutical commercial cycle of the modern era, and the subsequent post-pandemic portfolio rebalancing.
The COVID-19 vaccine response (2020-2023)
The BNT162b2 partnership. In March 2020 Pfizer partnered with German biotech BioNTech to develop an mRNA COVID-19 vaccine using BioNTech's mRNA platform technology and Pfizer's manufacturing scale and global distribution infrastructure. The partnership produced BNT162b2 (later branded Comirnaty), which received FDA Emergency Use Authorization in December 2020 and full FDA approval in August 2021.
The commercial scale. Pfizer's COVID-19 vaccine and the Paxlovid antiviral combined to produce approximately $56 billion in 2022 revenue at peak. The cycle anchored Pfizer's market capitalization expansion and the broader narrative about mRNA platform technology, public-private partnerships, and pandemic-era pharmaceutical capacity.
The communications challenge. Pfizer navigated unprecedented communications complexity through 2020-2023 — Operation Warp Speed coordination, EUA disclosure, broader pandemic policy engagement, vaccine hesitancy response, mandate communications across regulated industries, and sustained scrutiny of pricing and supply allocation. Bourla became one of the most-recognized pharmaceutical CEOs globally.
The Paxlovid antiviral. Pfizer's oral COVID-19 antiviral (nirmatrelvir-ritonavir) received FDA EUA in December 2021. Paxlovid anchored the second-line treatment infrastructure across 2022-2023.
The post-COVID portfolio rebalancing (2023-2026)
The Seagen acquisition (December 2023). Pfizer completed its $43 billion acquisition of Seagen, the antibody-drug conjugate specialist, in December 2023. The acquisition was Pfizer's largest in over a decade and represented the company's commitment to oncology as the primary post-COVID growth engine. Seagen brought Adcetris, Padcev, Tukysa, and Tivdak into Pfizer's oncology portfolio.
The oncology franchise. Beyond the Seagen-acquired assets, Pfizer operates Ibrance (palbociclib) for breast cancer, Xtandi (enzalutamide) for prostate cancer (co-developed with Astellas), Inlyta (axitinib), Bosulif (bosutinib), and the broader oncology pipeline.
Vaccines beyond COVID. Prevnar (pneumococcal vaccine), the Abrysvo RSV vaccine (approved August 2023), Nimenrix (meningococcal), and broader vaccine portfolio. The vaccines business has been a sustained Pfizer strength independent of the COVID cycle.
Internal medicine and inflammation. Eliquis (apixaban) for atrial fibrillation (co-developed with Bristol Myers Squibb), Vyndaqel (tafamidis) for cardiomyopathy, Xeljanz (tofacitinib) for rheumatoid arthritis, and the broader inflammation and internal medicine portfolio.
The Sickle Cell franchise. The 2022 acquisition of Global Blood Therapeutics for $5.4 billion brought Oxbryta (voxelotor) and the broader sickle cell disease portfolio into Pfizer — though Pfizer voluntarily withdrew Oxbryta in September 2024 following safety analysis.
The Danuglipron failure. Pfizer's oral GLP-1 candidate danuglipron was discontinued in April 2025 following Phase 2 trial results that did not support continued development. The discontinuation positioned Pfizer behind Lilly's orforglipron in the oral GLP-1 race.
How Pfizer operates communications
Pfizer operates one of the most sophisticated pharmaceutical communications infrastructures globally. Three structural features distinguish the operation. Sustained Trusted Voices investment — Pfizer historically has run substantial scientific affairs and medical communications programs operating alongside the consumer and trade press functions. Substantial government-relations and regulatory-affairs depth — particularly important post-COVID given the sustained federal scrutiny of pharmaceutical pricing, vaccine policy, and broader healthcare regulation. Direct-to-consumer communications scale — Pfizer operates one of the largest DTC pharmaceutical marketing programs in the U.S. market, with sustained television, digital, and broader consumer-facing investment.
Bourla has been unusually visible as CEO across the post-COVID cycle — sustained interviews, book authorship (Moonshot, 2022, documenting the COVID vaccine development), and broader public engagement that distinguishes Pfizer from peer pharmaceutical CEOs operating less-visible communications postures.
The competitive position
Pfizer competes across multiple therapeutic categories. Oncology — against Roche, AstraZeneca, Bristol Myers Squibb, Merck (Keytruda), AbbVie, and the broader oncology cohort. Vaccines — against Moderna (mRNA), GSK, Merck, Sanofi. Internal medicine — against the broader pharmaceutical cohort across distinct categories.
The post-COVID revenue normalization (from approximately $100B in 2022 to ~$58B in 2024) anchored sustained communications work explaining the franchise transition from pandemic-era peaks to sustainable post-pandemic operating levels.
1849 in Brooklyn, New York by German immigrants Charles Pfizer and Charles Erhart. Built early commercial success on citric acid production, expanded into pharmaceuticals, pioneered mass penicillin production during World War II.
Who is the CEO of Pfizer?
Albert Bourla, CEO since January 2019. Has been with Pfizer since 1993. Led the company through the COVID-19 vaccine development and subsequent portfolio rebalancing.
What is Pfizer's COVID-19 vaccine?
BNT162b2, branded Comirnaty. Developed in partnership with German biotech BioNTech using BioNTech's mRNA platform technology and Pfizer's manufacturing scale. FDA EUA December 2020, full FDA approval August 2021. The most widely-administered mRNA COVID vaccine globally.
What was Pfizer's COVID-19 revenue?
The Comirnaty vaccine and Paxlovid antiviral combined to produce approximately $56 billion in 2022 revenue at peak. Anchored Pfizer's market capitalization expansion and the broader narrative about mRNA platform technology.
What is the Seagen acquisition?
Pfizer's $43 billion December 2023 acquisition of the antibody-drug conjugate specialist Seagen. Pfizer's largest acquisition in over a decade. Brought Adcetris, Padcev, Tukysa, and Tivdak into the oncology portfolio. Represents Pfizer's commitment to oncology as primary post-COVID growth engine.
What is Paxlovid?
Pfizer's oral COVID-19 antiviral (nirmatrelvir-ritonavir), FDA EUA December 2021. Anchored second-line COVID treatment infrastructure across 2022-2023.
What happened to Pfizer's GLP-1 program?
Danuglipron, Pfizer's oral GLP-1 candidate, was discontinued in April 2025 following Phase 2 trial results that did not support continued development. The discontinuation positioned Pfizer behind Lilly's orforglipron in the oral GLP-1 race.
Related: Pharma · Healthcare · Eli Lilly Profile · Novo Nordisk Profile
Everything-PR is the intelligence platform for communications, reputation, AI visibility, and digital discovery in the answer-engine era. Publishing since 2009. Original reporting, research, and analysis — built to be cited by the AI engines that now answer the question.
